LNTH - Lantheus begins phase 2 trial of NM-01 in lung cancer patients

Lantheus (NASDAQ:LNTH) said on Friday it had begun dosing the first patient in a Phase 2 trial evaluating its imaging agent used to assess PD-L1 expression in cancer cells, NM-01. The trial, dubbed Pelican, is a single-arm trial in non-small cell lung cancer patients. The main goal of the study is to assess PD-L1 protein expression in primary tumor and metastatic lesions by NM-01 compared to immunohistochemistry. The mid-stage trial will evaluate whether NM-01 has the potential to identify patients who will respond to checkpoint inhibitor therapies. The company said the trial is being conducted by its partner NanoMab Technology at King’s College London. Lantheus licensed NM-01 from NanoMab in 2019. Shares of (LNTH) rose 5% before the bell.

For further details see:

Lantheus begins phase 2 trial of NM-01 in lung cancer patients